

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/625,989  
Applicant : Kenneth David Reginald SETCHELL, *et al.*  
Filed : July 24, 2003  
TC/A.U. : 1616  
Examiner : Alton N. Pryor

Docket No. : 3515-104  
Customer No. : 06449  
Confirmation No. : 1706

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants submit herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449.

The Commissioner is authorized to charge the requisite fee or credit any overpayment to Deposit Account No. 02-2135.

Respectfully submitted,

By 

Patrick T. Skacel  
Attorney for Applicants  
Registration No. 47,948  
ROTHWELL, FIGG, ERNST & MANBECK, p.c.  
Suite 800, 1425 K Street, N.W.  
Washington, D.C. 20005  
Telephone: (202) 783-6040

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	10/625,989
				Filing Date	July 24, 2003
				First Named Inventor	Kenneth David Reginald SETCHELL
				Group Art Unit	1616
				Examiner Name	Alton N. Pryor
				Confirmation No.	1706
Sheet	1	of	1	Attorney Docket Number	3515-104
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	1	ADLERCREUTZ, H., <i>et al.</i> , Excretion of The Lignans Enterolactone and Enterodiol and of Equol in Omnivorous and Vegetarian Postmenopausal Women and In Women with Breast Cancer. <u>The Lancet</u> , December 11, 1982, 1295-1299.			
	2	AKAZA, H., <i>et al.</i> , Is Daidzein Non-metabolizer High Risk for Prostate Cancer? A case-controlled Study of Serum Soybean Isoflavone Concentration. <u>Jpn J Clin Oncol</u> , 2002, 32(8): 296-300.			
	3	INGRAM, D., <i>et al.</i> , Case-control study of phyto-estrogens and breast cancer. <u>The Lancet</u> , October 4, 1997, Vol. 350, 990-994.			
	4	KOSTELAC, D.G., <i>et al.</i> , Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. <u>J. Agric 7632-5 Food Chem</u> , 2003, 51(26): 7632.5.			
	5	LEPHART, E., Antiaging Effects of Equol: A Unique Antiandrogenic Isoflavone Metabolite and its influence in Stimulating Collagen Deposition in Human Dermal Monolayer Fibroblasts, <u>J Am Acad Dermatol</u> , March 2006, AB103.			AB
	6	LEPHART, E.D., Equol: A unique anti-androgenic isoflavone metabolite stimulates Collagen (I and III), elastin and human fibroblast proliferation and inhibits matrix metalloproteinases and elastase in 3D cultures via FACS analysis, <u>J Am Acad Dermatol</u> , March 2005, 85.			AB
	7	LUND, T.D., "Altered sexually dimorphic nucleus of the preoptic area (SDN-POA) volume in adult Long-Evans rats by dietary soy phytoestrogens; <u>Brain Research</u> , 2001, 914(1-2).			
	8	SETCHELL, D.R., <i>et al.</i> , S-Equol, a potent ligand for estrogen receptor $\beta$ , is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora, <u>The American Journal of Clinical Nutrition</u> , May 2005, 81, 1072-1079.			
	9	WEBER, K.S., Dietary Soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5 $\alpha$ -reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats, <u>Journal of Endocrinology</u> , 2001, 170:591-599.			
	10	Office Action dated February 27, 2007 from related U.S. Application No. 10/625,934.			
Examiner Signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.